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Abstract
Background: Use of core outcome sets in research has been proposed as a method for countering the problems
caused by heterogeneity of outcome measure reporting. Heterogeneity of outcome measure reporting occurs in
Hirschsprung’s disease (HD) research and is limiting the development of a robust evidence base to support
clinical practice.
Methods: Candidate outcome measures have been identified through a systematic review. These outcome
measures will form the starting point for a three-phase online Delphi process to be carried out in parallel by
three panels of experts. Panel 1 is a neonatal panel; panel 2 is a non-neonatal panel; and panel 3 is a lay panel.
In round 1, experts will be asked to score the previously identified outcome measures from 1 to 9 based on how
important they think the measures are in determining the overall success of their/their child’s/their patient’s HD.
In round 2, experts will be presented with the same list of outcome measures and graphical representations of
how their panel scored that outcome in round 1. They will be asked to re-score the outcome measure, taking
into account how important other members of their panel felt it to be. In round 3, experts will again be asked
to re-score each outcome measure, but this time they will receive a graphical representation of the distribution
of scores from all three panels, which they should take into account when re-scoring. Following round 3 of the
Delphi process, 40 experts will be invited to attend a face-to-face consensus meeting. Participants will be invited
in a purposive manner to obtain balance between the different panels. Results of the Delphi process will be
discussed, and outcomes will be re-scored. Outcome measures where >70% of participants at the meeting scored
it 7–9 and <15% scored it 1–3 will form the core outcome set.
Discussion: Development of a core outcome set will help to reduce heterogeneity of outcome measure
reporting in HD. This will increase the quality of research taking place and ultimately improve care provided
to infants with HD.
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Background
Hirschsprung’s disease (HD) is a condition where the
nerves of the myenteric plexus do not develop correctly
along the full length of the colon. It results in infants be-
ing unable to open their bowels properly, and it affects
approximately 1.7 in 10,000 live births in the United
Kingdom and Ireland. Treatment is usually with surgical
resection of the affected sections of bowel within the
first few months of life. There are currently three main
approaches to conducting the definitive pull-through
procedure required for treatment of HD: the open
approach, the purely transanal approach [1] and the
laparoscopically assisted approach [2]. There are also
multiple methods used to perform colorectal/coloanal
anastomosis [3–5]. To date, authors of systematic re-
views have been unable to reliably determine the gold
standard intervention for HD [6, 7]. One of the key
factors preventing identification of a gold standard inter-
vention is heterogeneity of outcome measure reporting
in primary studies.
Heterogeneity of outcome measure reporting results in
difficulties with synthesising data from individual stud-
ies, as well as resulting in studies being prone to report-
ing bias and a lack of patient relevance [8]. Within HD
research, such heterogeneity has resulted in the conduct
of studies focused on hospital-based measures or surro-
gate markers of success, as opposed to outcomes that
are deemed important by people with HD or their fam-
ilies [7]. Owing to the low incidence of HD, conducted
studies are frequently limited in size. In this situation, it
is essential that all conducted studies be relevant to
patients, report full data and be easy to synthesise with
other work.
A core outcome set (COS) is a group of outcome mea-
sures that have been identified by key stakeholder
groups as the most important in determining the success
of treatment of a particular condition [8, 9]. Use of a
COS to define the outcome measures which are the
minimum it is acceptable to investigate and report in a
particular field of research has been shown to be a suc-
cessful method for countering heterogeneity in outcome
measure reporting [10]. When development of a COS
for HD is combined with increased collaboration be-
tween research institutions, the ability of HD research to
answer clinically relevant questions will be increased,
and generation of robust evidence-based management
guidelines will be facilitated.
Methods
Ethics and registration
The Health Research Authority deemed the project to be
service evaluation/service development, and therefore
review by a National Health Service (NHS) Research
Ethics Committee was not deemed necessary. Information
on the nature of the study will be provided to participants
prior to registration and again prior to completion of the
first round of the survey. Potential participants are given
contact details for staff within the National Perinatal
Epidemiology Unit (NPEU) from whom further informa-
tion can be obtained or with whom they can discuss the
study further. Detailed information is also available on the
study website (http://www.npeu.ox.ac.uk/nets). Consent to
participate in the study is implied by completion of the
registration questionnaire and data collection question-
naires. Participants can withdraw from the study at any
time, either by contacting the study team or by simply not
completing a data collection questionnaire. The study has
been registered with the Core Outcome Measures in
Effectiveness Trials (COMET) Initiative (http://www.co-
met-initiative.org).
Scope of the core outcome set
The developed COS is intended to be used to assess the
overall success of treatment of an infant born with HD.
This will involve outcome measures identified as im-
portant from diagnosis through into adulthood. We
have kept the scope of the COS broad for two reasons.
First, although HD research currently covers multiple
different areas of treatment, there are only a limited
number of studies being conducted that use robust
methodology [11]. Any intervention that is aimed at
improving the overall robustness of research taking
place therefore needs to be as broadly applicable as
possible. Second, whilst research into the treatment of
infants with HD will fall into three broad areas (man-
agement of enterocolitis, definitive surgery and re-do
surgery), it is the combination of success of treatment
in these three areas that matters. Developing a COS to
reflect treatment success in one area whilst neglecting
the importance of the other two areas would therefore
likely not meet the primary aim of developing the COS.
The following are key objectives of the trial:
1. To determine which outcomes are currently
reported in studies comparing surgical treatments
for HD and assess the quality of reporting
2. To prioritise outcomes from patient/parent, paediatric
surgical and non-surgical clinician perspectives
3. To achieve consensus between key stakeholders on a
COS for assessing how successful the overall
treatment of an infant with HD has been
4. To compare and contrast outcomes prioritised by
patients/parents, surgeons and non-surgical clinicians
Wider aims of the trial are as follows:
1. To develop methodology for addressing difficulties
likely to be encountered in development of COSs in
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all paediatric surgical conditions, including the
following:
a. Recruitment of parents and patients
b. Incorporation of opinions from clinicians whose
priorities vary dependent on their specialty, or age
they encounter the child
Design
There will be four key stages to development of the
COS:
1. Systematic review to identify currently reported
outcomes
2. Development of a panel of experts
3. Three-phase online Delphi process
4. Consensus meeting
Systematic review
An already conducted systematic review has been used as
the basis for phase 1 of the Delphi process (Allin B, Irvine A,
Patni N, Knight M. Variability of outcome reporting in
Hirschsprung’s disease and gastroschisis: a systematic review,
unpublished). The aim of this systematic review was to iden-
tify every outcome measure investigated by studies that have
been conducted since 2010 and involved more than ten
participants, and in which two or more interventions for HD
were compared. The systematic review included both obser-
vational and interventional studies and thereby gave a broad
overview of outcomes that are currently investigated in the
HD literature. The outcome domains identified by this
systematic review will be used as the outcomes to be scored
in phase 1 of the Delphi process. Specific time points and
methods of measurement will not be incorporated into the
outcomes to be scored in phase 1. These components will
instead be identified through subsequent literature review;
discussion at the consensus meeting; and, if necessary, a
separate ‘how to measure’ meeting. The use of systematic re-
views to inform phase 1 of a Delphi process is recommended
by the COMET Initiative [12] and has previously been used
in the development of other COSs, including in the Manage-
ment of Otitis Media with Effusion in Cleft Palate study [13].
Panel assembly
Expert identification and recruitment
To ensure appropriate breadth of recruitment, experts will
be recruited under three broad categories (disciplines, or-
ganisations and literature) and then within sub-categories,
which include, amongst others, paediatric surgeons, paedi-
atric gastroenterologists, parents, the Royal College of
Paediatrics and Child Health, and the Journal of Paediatric
Surgery. Members of the study management group (SMG)
will draw up an exhaustive list of sub-categories from
which at least two participants must be identified. Experts
known to the SMG and fitting into one of these sub-
categories will be identified first, prior to expanding re-
cruitment using methods specific to each sub-category.
Examples of expert recruitment include the following:
 Contacting all paediatric surgeons listed on the
British Association of Paediatric Surgeons register of
practitioners as having a specialist interest in the
treatment of infants with HD
 Advertising to people with HD and their parents via
mailing lists established by the Hirschsprung’s &
Motility Disorders Support Network
 Contacting the editors of key paediatric surgical
journals and asking them to identify members of
their editorial board with an interest in HD
 Advertising to paediatric gastroenterologists via
mailing lists of the British Society of Paediatric
Gastroenterology Hepatology and Nutrition
All identified experts will be emailed a link to an on-
line form on which they can detail their involvement in
HD and express their interest in participating in the
study. Experts will also be asked to provide the names of
anyone else they feel would be appropriate to invite to
participate in the study. At this stage, we are seeking to
clarify the suitability of experts for participation in the
study and to identify further potential experts. This
process will be repeated for the names provided by
already-contacted experts. Expert recruitment will con-
tinue until a minimum of 50 experts, at least 2 in each
category, have been recruited.
Following confirmation of their eligibility to participate
in the study, experts will be sent a link to a customised
online database hosted on the secure servers of the
University of Oxford and developed using LimeSurvey
(https://www.limesurvey.org), from which they can ac-
cess phase 1 of the Delphi process.
Facilitating consensus
To be truly representative of the broad experience of
those involved in HD, it is important that the COS re-
flect the opinions of people with HD, their parents, and
a broad spectrum of clinicians, including those who treat
people with HD later in life (e.g., paediatric gastroenter-
ologists), as well as in early infancy (e.g., neonatologists).
These different groups may have different priorities,
which could cause difficulties in attaining consensus on
a single set of important outcome measures. Thus, to
facilitate achieving consensus, experts will be separated
into three different panels:
1. Neonatal panel: Clinicians whose responsibility
includes management in the neonatal period (but
may also include management outside the neonatal
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period). This group will include neonatologists and
paediatric surgeons.
2. Non-neonatal panel: Researchers with expertise in
HD management and clinicians responsible for
management primarily outside the neonatal period.
This group will include specialist nurses and
paediatricians.
3. Lay panel: Parents (or other equivalent guardian)
and adults born with HD.
Delphi process
Phase 1 data collection
To maintain anonymity and ease data collection, a cus-
tomised online system will be developed to conduct a
three-phase Delphi process run in parallel for the
neonatal, non-neonatal and lay panels. In phase 1, par-
ticipants will be presented, in alphabetical order, with
outcomes identified from the systematic review. Lay
equivalents will be developed for each outcome measure,
and these will be used instead of scientific terms for the
parent/patient panel. These terms will be developed in
conjunction with the NPEU’s parent advisory group.
Participants will be asked to give each outcome meas-
ure a score from 1 to 9, where 1, 2 and 3 are ‘not that
important’; 4, 5 and 6 are ‘important’; and 7, 8 and 9 are
‘really important’. The Grading of Recommendations As-
sessment, Development and Evaluation (GRADE) scale
of measurement has been chosen for use in scoring out-
come measures on the basis of recommendations from
the COMET Initiative [12]. After scoring all outcome
measures identified by the systematic review, partici-
pants will be asked to list any additional outcome mea-
sures they feel are important in determining the success
of treatment of HD, but which we have not already
asked them to score. These outcomes will not be scored
in phase 1.
Data will be collected over a 4-week period for each
phase of the Delphi process. Participants who have not
completed the survey will be sent reminders via email
when they have 2 weeks, 1 week and 48 h remaining for
completion of the survey. Participants who have not com-
pleted the questionnaire within 4 weeks of the phase start
will be deemed not to have completed that phase. Testing
has suggested that completion of the phase 1 question-
naire will take participants approximately 15 minutes.
Phase 1 analysis
The number of experts invited to participate, registering
to participate and completing phase 1 of the Delphi
process from each sub-category will be recorded.
Outcomes will be analysed separately for each panel,
with descriptive statistics calculated, including medians
and inter-quartile ranges. All outcomes will be carried
forward to phase 2. Additional outcomes listed by experts
in phase 1 will be assessed by the SMG to determine
whether they represent de novo outcomes and whether
they fall within the scope of the COS. Those that are
deemed to both fall within the scope of the COS and rep-
resent a de novo outcome will be taken forward to phase
2 and scored alongside the outcome measures scored in
phase 1. We anticipate that there will be between 10 and
20 outcomes that meet these criteria.
Phase 2 data collection
Experts completing phase 1 will be invited to participate
in phase 2 and asked to re-score each outcome on the
basis of the following:
 The phase 1 score they assigned it
 Descriptive statistics from their panel
Descriptive statistics will be represented numerically
and graphically.
Phase 2 analysis
Descriptive statistics will again be calculated. Bias from
loss of experts between rounds will be assessed by deter-
mining if there is any difference in median round 1 scores
for each outcome measure between experts who have
completed both phases and experts who completed only
phase 1. All outcomes will be carried forward to phase 3.
Phase 3 data collection
Experts completing phase 2 will be invited to participate
in phase 3 and asked to re-score each outcome on the
basis of the following:
 The phase 2 score they assigned it
 Round 2 descriptive statistics from all three panels
Phase 3 analysis
Analysis will be conducted as per phase 2.
Generation of core outcome set: consensus meeting
A roundtable consensus meeting with an independent,
non-voting chair will be held at a central location in the
United Kingdom to identify the final COS and determine
how to measure those outcomes that form it. Partici-
pants will be invited to attend the consensus meeting in
such a way as to ensure participation from all three
panels that is as even as possible, with a range of experi-
ences represented.
The final COS will comprise those outcome measures
where >70% of participants at the consensus meeting
score the outcome measure between 7 and 9 and less
than 15% of participants at the consensus meeting score
the outcome measure between 1 and 3. Every outcome
measure assessed in phase 3 of the Delphi process will
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be discussed and re-scored by meeting participants using
the same scale as for the online portion of the study.
Prior to the meeting, participants will be given a sum-
mary of the final results of the Delphi process. During
the meeting, they will be shown a graphical representa-
tion of the scores for each outcome measure (Fig. 1) and
given the opportunity to explore the reasons for any
differences in scores between panels. After discussion of
each outcome measure, re-scoring will take place
electronically and anonymously using the TurningPoint
system (Turning Technologies, Youngstown, OH, USA).
These scores will be used to determine whether an out-
come measure is included in the COS.
Following completion of the consensus meeting, a
consensus document will be drafted and put forward to
participants for approval. This document will be pre-
sented at appropriate international meetings and pub-
lished in peer-reviewed journals.
Data management
All data will be directly entered into a customised database
by participants. Data will be stored securely on servers
within the NPEU and will be managed as per standard op-
erating protocols. Only appropriate members of the study
team will have access to the data. Data analysis will be
conducted by BA and MK. Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
checklists are provided in Additional file 1.
Discussion
Development of the COS will identify outcomes that are
important to people with HD, their parents and key clinical
stakeholder groups. Use of such a COS in future research
will help to counter many of the previously identified prob-
lems caused by heterogeneity of outcome measure report-
ing, including a lack of patient relevance, a high risk of
reporting bias and difficulty in conducting meta-analyses.
Involvement of multiple stakeholder groups in devel-
opment of the COS is one of its major strengths and will
ensure that it is relevant to patients and applicable
across a broad range of clinical settings. This is the first
time that people with HD and their parents will have
been involved in identification of key outcomes for
research studies in a robust, replicable manner, and this
Fig. 1 Sample consensus meeting slide
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effort will help to ensure that future research has a
genuine patient-centred focus.
Although the COS will seek to involve participants from
a range of countries involved in the management of infants
with HD, none will be recruited from low- or middle-
income countries. This is because it is felt likely that prior-
ities in those countries will be very different from those in
high-income countries, and therefore inclusion of partici-
pants from those settings would create too heterogeneous a
study population. Given the lack of involvement of these
countries and their likely difference in priorities, the most
significant limitation of this COS is therefore that it is likely
to be valid only for use in high-income countries.
Despite the likely limitation of its applicability to high-
income countries, we believe the developed COS will
have application across a wide range of HD research.
One of the major challenges associated with develop-
ment of the COS, however, will be ensuring that its use
is taken up by other research groups. To ensure that this
occurs, key paediatric surgical stakeholders, including
the British Association of Paediatric Surgeons, are in-
volved in development of the COS and will endorse the
study to their memberships. Funding has also been ob-
tained to conduct a UK-wide cohort study to investigate
the identified core outcomes in infants with HD as they
turn 6 years of age. Implementing the COS in a study
with the power to address key clinical questions will help
to demonstrate that its use is both feasible and desirable.
Use of COSs in other specialties has been shown to im-
prove the quality of research taking place [10]. This will
be the first time a COS has been developed for use in a
paediatric surgical condition, and we hope it will create
the infrastructure and methodology required to replicate
the process in other conditions, leading to a generalised
increase in the robustness of the evidence base used to
support clinical practice in paediatric surgery.
Trial status
Data collection finished after submission of the manusript,
but prior to publication.
Additional file
Additional file 1: SPIRIT checklist detailing where key sections of text
can be identified within the protocol. (DOC 126 kb)
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